Vera Therapeutics (NASDAQ:VERA) PT Lowered to $62.00

Vera Therapeutics (NASDAQ:VERA) had its price objective decreased by equities research analysts at JPMorgan Chase & Co. from $65.00 to $62.00 in a research report issued on Tuesday, Benzinga reports. The firm presently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s target price would suggest a potential upside of 72.99% from the stock’s current price.

Separately, Raymond James lifted their target price on shares of Vera Therapeutics from $57.00 to $68.00 and gave the stock a “strong-buy” rating in a research report on Friday, May 10th. One investment analyst has rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $42.43.

Vera Therapeutics Stock Down 0.4 %

Shares of NASDAQ VERA opened at $35.84 on Tuesday. The company has a quick ratio of 21.43, a current ratio of 21.43 and a debt-to-equity ratio of 0.15. Vera Therapeutics has a 52 week low of $9.24 and a 52 week high of $50.78. The firm has a 50-day moving average price of $36.26 and a 200 day moving average price of $39.82. The stock has a market capitalization of $1.96 billion, a price-to-earnings ratio of -17.48 and a beta of 0.99.

Vera Therapeutics (NASDAQ:VERA) last announced its earnings results on Thursday, August 8th. The company reported ($0.62) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.56) by ($0.06). Equities research analysts anticipate that Vera Therapeutics will post -2.34 EPS for the current fiscal year.

Institutional Investors Weigh In On Vera Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of VERA. SG Americas Securities LLC purchased a new stake in Vera Therapeutics in the fourth quarter valued at approximately $119,000. Public Employees Retirement Association of Colorado purchased a new stake in Vera Therapeutics in the second quarter valued at approximately $135,000. Ameritas Investment Partners Inc. grew its holdings in Vera Therapeutics by 20.8% in the first quarter. Ameritas Investment Partners Inc. now owns 4,000 shares of the company’s stock valued at $172,000 after purchasing an additional 688 shares during the period. Cetera Advisors LLC purchased a new stake in Vera Therapeutics in the first quarter valued at approximately $235,000. Finally, Capstone Investment Advisors LLC purchased a new stake in Vera Therapeutics in the first quarter valued at approximately $248,000. 99.21% of the stock is currently owned by hedge funds and other institutional investors.

Vera Therapeutics Company Profile

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.